Goldman Sachs Group Inc Arcus Biosciences, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 703,336 shares of RCUS stock, worth $11.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
703,336
Previous 636,774
10.45%
Holding current value
$11.2 Million
Previous $9.7 Million
10.89%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding RCUS
# of Institutions
201Shares Held
51.7MCall Options Held
236KPut Options Held
141K-
Black Rock Inc. New York, NY9.76MShares$156 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.47MShares$87.2 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.48MShares$55.4 Million0.48% of portfolio
-
State Street Corp Boston, MA3.01MShares$48 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.44MShares$38.8 Million0.1% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.15B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...